A Phase II Study to Evaluate the Efficacy of Regorafenib in C-kit Mutated Metastatic Malignant Melanoma Failed First-Line Dacarbazine, Temozolomide or Immune Therapy
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 11 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated